AbbVie publishes slides outlining $10.9 billion all-cash acquisition of Apogee Therapeutics

Apogee Therapeutics, Inc.
AbbVie, Inc.

Apogee Therapeutics, Inc.

APGE

0.00

AbbVie, Inc.

ABBV

0.00
  • AbbVie agreed to buy Apogee Therapeutics in an all-cash deal priced at USD 135.11 a share, valuing the equity at USD 10.9 billion.
  • Implied transaction value about USD 10.1 billion net of estimated cash and marketable securities; AbbVie plans to fund the purchase with debt.
  • Closing expected in Q3 2026, subject to shareholder and regulatory approvals; AbbVie targets a net leverage ratio of 2x within 2-3 years.
  • Deal adds Apogee’s long-acting immunology pipeline, led by IL-13 antibody zumilokibart for atopic dermatitis with Q12W-Q24W dosing; Phase 3 start 2H26.
  • AbbVie expects adjusted diluted EPS dilution of about USD 0.14 in 2026 and USD 0.46 in 2027; accretion expected from 2032.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.